This work has resulted in two drugs currently on the market, as well as other compounds currently in clinical trials. The drug Humira® (adalimumab), marketed by Abbott, provides a treatment for inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and plaque psoriasis. Humira® is now reported to be the top selling drug in the world.
Benlysta® (belimumab), which was developed by GlaxoSmithKline and Human Genome Sciences, was approved in the United States for the treatment of the most common type of lupus—a chronic, life-threatening autoimmune disease—in the spring of last year. At that time, Benlysta® became the first new drug for lupus in 50 years.
This year, 41 nominations from Argentina, Bulgaria, Canada, Costa Rica, Cuba, France, Germany, Holland, Israel, Italy, Japan, Mexico, Russia, Sweden, Switzerland, Turkey, United Kingdom, United States and Spain were in the running for the Prince of Asturias Award for Scientific and Technical Research. This prize is the fourth of eight awards bestowed each year by the Prince of Asturias Foundation. The others are in the fields of the arts, communications and humanities, literature, sports, social sciences, international cooperation, and concord (peace).
The Prince of Asturias Foundation was founded in the city of Oviedo on September 24, 1980, at a formal ceremony presided over by His Royal Highness the Prince of Asturias, heir to the throne of Spain, who was accompanied by his parents, Their Majesties the King and Queen of Spain.
The essential aims of the foundation are to consolidate links between the principality and the Prince of Asturias, and to contribute to encouraging and promoting the scientific, cultural, and humanistic values that form part of mankind's universal heritage.
|SOURCE The Scripps Research Institute|
Copyright©2010 PR Newswire.
All rights reserved